These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

382 related items for PubMed ID: 31002919

  • 21. NLRP3 inflammasome inhibition with MCC950 improves diabetes-mediated cognitive impairment and vasoneuronal remodeling after ischemia.
    Ward R, Li W, Abdul Y, Jackson L, Dong G, Jamil S, Filosa J, Fagan SC, Ergul A.
    Pharmacol Res; 2019 Apr; 142():237-250. PubMed ID: 30818045
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Targeting the NLRP3 Inflammasome With Inhibitor MCC950 Prevents Aortic Aneurysms and Dissections in Mice.
    Ren P, Wu D, Appel R, Zhang L, Zhang C, Luo W, Robertson AAB, Cooper MA, Coselli JS, Milewicz DM, Shen YH, LeMaire SA.
    J Am Heart Assoc; 2020 Apr 07; 9(7):e014044. PubMed ID: 32223388
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Activation of NLRP3 inflammasome up-regulates TREM-1 expression in murine macrophages via HMGB1 and IL-18.
    Zhong WJ, Duan JX, Liu T, Yang HH, Guan XX, Zhang CY, Yang JT, Xiong JB, Zhou Y, Guan CX, Li Q.
    Int Immunopharmacol; 2020 Dec 07; 89(Pt A):107045. PubMed ID: 33045564
    [Abstract] [Full Text] [Related]

  • 28. Inhibiting the NLRP3 inflammasome with MCC950 promotes non-phlogistic clearance of amyloid-β and cognitive function in APP/PS1 mice.
    Dempsey C, Rubio Araiz A, Bryson KJ, Finucane O, Larkin C, Mills EL, Robertson AAB, Cooper MA, O'Neill LAJ, Lynch MA.
    Brain Behav Immun; 2017 Mar 07; 61():306-316. PubMed ID: 28003153
    [Abstract] [Full Text] [Related]

  • 29. NLRP3 inflammasome inhibition attenuates subacute neurotoxicity induced by acrylamide in vitro and in vivo.
    Sui X, Yang J, Zhang G, Yuan X, Li W, Long J, Luo Y, Li Y, Wang Y.
    Toxicology; 2020 Feb 28; 432():152392. PubMed ID: 32014472
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Delayed NLRP3 inflammasome inhibition ameliorates subacute stroke progression in mice.
    Bellut M, Bieber M, Kraft P, Weber ANR, Stoll G, Schuhmann MK.
    J Neuroinflammation; 2023 Jan 04; 20(1):4. PubMed ID: 36600259
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Mitochondrial dysfunction induces NLRP3 inflammasome activation during cerebral ischemia/reperfusion injury.
    Gong Z, Pan J, Shen Q, Li M, Peng Y.
    J Neuroinflammation; 2018 Aug 28; 15(1):242. PubMed ID: 30153825
    [Abstract] [Full Text] [Related]

  • 36. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases.
    Coll RC, Robertson AA, Chae JJ, Higgins SC, Muñoz-Planillo R, Inserra MC, Vetter I, Dungan LS, Monks BG, Stutz A, Croker DE, Butler MS, Haneklaus M, Sutton CE, Núñez G, Latz E, Kastner DL, Mills KH, Masters SL, Schroder K, Cooper MA, O'Neill LA.
    Nat Med; 2015 Mar 28; 21(3):248-55. PubMed ID: 25686105
    [Abstract] [Full Text] [Related]

  • 37. Efficacy and Pharmacology of the NLRP3 Inflammasome Inhibitor CP-456,773 (CRID3) in Murine Models of Dermal and Pulmonary Inflammation.
    Primiano MJ, Lefker BA, Bowman MR, Bree AG, Hubeau C, Bonin PD, Mangan M, Dower K, Monks BG, Cushing L, Wang S, Guzova J, Jiao A, Lin LL, Latz E, Hepworth D, Hall JP.
    J Immunol; 2016 Sep 15; 197(6):2421-33. PubMed ID: 27521339
    [Abstract] [Full Text] [Related]

  • 38. Therapeutic potential of MCC950, a specific inhibitor of NLRP3 inflammasome.
    Li H, Guan Y, Liang B, Ding P, Hou X, Wei W, Ma Y.
    Eur J Pharmacol; 2022 Aug 05; 928():175091. PubMed ID: 35714692
    [Abstract] [Full Text] [Related]

  • 39. Ameliorative effect of selective NLRP3 inflammasome inhibitor MCC950 in an ovalbumin-induced allergic rhinitis murine model.
    Zhang W, Ba G, Tang R, Li M, Lin H.
    Int Immunopharmacol; 2020 Jun 05; 83():106394. PubMed ID: 32193102
    [Abstract] [Full Text] [Related]

  • 40. MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition.
    Coll RC, Hill JR, Day CJ, Zamoshnikova A, Boucher D, Massey NL, Chitty JL, Fraser JA, Jennings MP, Robertson AAB, Schroder K.
    Nat Chem Biol; 2019 Jun 05; 15(6):556-559. PubMed ID: 31086327
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.